 In 2008, Seppic adjuvants were used to develop CimaVax, the first therapeutic vaccine to treat lung cancer.SEPPIC has research partnerships in the fields of health, nutrition, personal care, and vaccines with French and international companies, including the Japanese chemical giant Shin-Etsu.Seppic is also involved with the Cosmetic Valley business cluster.